Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AbbVie Inc. Director's Dealing 2017

Oct 31, 2017

29755_dirs_2017-10-31_df4159b9-c9cb-432b-ab8c-762dbc64843b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2017-10-30

Reporting Person: Gosebruch Henry O (Chief Strategy Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-10-30 Common stock, $0.01 par value S 2150 $89.3823 Disposed 81287 Direct
2017-10-30 Common stock, $0.01 par value S 11568 $90.4922 Disposed 69719 Direct
2017-10-30 Common stock, $0.01 par value S 4482 $91.2203 Disposed 65237 Direct
2017-10-30 Common stock, $0.01 par value S 100 $92.02 Disposed 65137 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common stock, $0.01 par value 1433 Indirect

Footnotes

F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.93 to $89.86, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.94 to $90.94, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.95 to $91.84, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: Balance in AbbVie Savings Program as of October 30, 2017.